Photo taken from IASLC/X
May 2, 2024, 14:14
Stephen V Liu discusses KRAS mutant NSCLC with Veluswamy and Mariana Brandao – IASLC
International Association for the Study of Lung Cancer (IASLC) shared on X:
“KRAS mutations are common in lung cancer, and while there are multiple approved/active KRAS inhibitors, they are specifically for the G12C mutation. Stephen V Liu discusses KRAS mutant Non-Small Cell Lung Cancer (NSCLC) with focus on non-G12C mutations with Veluswamy and Mariana Brandao.”
Additional information.
Source: IASLC/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19